Maura A. Markus
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Stifel Financial: Mid-Market Advisory Resilience Amid Rate Hikes. Recent analysis suggests Stifel's mid-market advisory and commission revenue may remain resilient despite interest rate hikes. This perspective is relevant as the stock trades near its 52-week low, with an RSI of 26.4 indicating oversold conditions. While other news items focus on third-party recognitions or unrelated targets, the focus on Stifel's core business durability provides key context for its current valuation.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Diebold Nixdorf partners stc pay Bahrain on digital‑physical services. Diebold Nixdorf announced a partnership with stc pay Bahrain to connect digital payment solutions with its physical financial service offerings. The collaboration aims to broaden the company’s reach in the Middle East by combining stc pay’s mobile platform with Diebold Nixdorf’s ATM and kiosk network. The firm also scheduled its 2026 third‑quarter investor call for Oct. 28, giving analysts an opportunity to discuss progress on converting its order backlog into cash.
Transaction History
| BR | ▲ Buy | Grant | 37 | $0 | 10/5/2026 | View on chart |
| BR | ▲ Buy | Grant | 100 | $0 | 10/5/2026 | View on chart |
| BR | ▲ Buy | Grant | 209 | $0 | 9/24/2026 | View on chart |
| BR | ▲ Buy | Grant | 98 | $0 | 7/2/2026 | View on chart |
| BR | ▲ Buy | Grant | 36 | $0 | 7/2/2026 | View on chart |
| BR | ▲ Buy | Grant | 239 | $0 | 6/10/2026 | View on chart |
| SF | ▲ Buy | Option Exercise | 2,812 | $0 | 6/4/2026 | View on chart |
| DBD | ▲ Buy | Grant | 2,621 | $0 | 5/22/2026 | View on chart |
| BR | ▲ Buy | Grant | 87 | $0 | 4/8/2026 | View on chart |
| BR | ▲ Buy | Grant | 29 | $0 | 4/8/2026 | View on chart |
| BR | ▲ Buy | Grant | 206 | $0 | 4/7/2026 | View on chart |
| BR | ▲ Buy | Grant | 62 | $0 | 1/5/2026 | View on chart |
| BR | ▲ Buy | Grant | 21 | $0 | 1/5/2026 | View on chart |
| BR | ▲ Buy | Grant | 160 | $0 | 12/10/2025 | View on chart |
| BR | ▲ Buy | Grant | 459 | $0 | 11/13/2025 | View on chart |
| BR | ▲ Buy | Grant | 57 | $0 | 10/2/2025 | View on chart |
| BR | ▲ Buy | Grant | 19 | $0 | 10/2/2025 | View on chart |
| BR | ▲ Buy | Grant | 140 | $0 | 9/17/2025 | View on chart |
| BR | ▲ Buy | Grant | 51 | $0 | 7/2/2025 | View on chart |
| BR | ▲ Buy | Grant | 16 | $0 | 7/2/2025 | View on chart |
| BR | ▲ Buy | Grant | 146 | $0 | 6/12/2025 | View on chart |
| SF | ▲ Buy | Option Exercise | 1,914 | $0 | 6/5/2025 | View on chart |
| BR | ▲ Buy | Option Exercise | 5,771 | $325K | 6/4/2025 | View on chart |
| BR | ▼ Sell | Open Market | 3,556 | $864K | 6/4/2025 | View on chart |
| DBD | ▲ Buy | Grant | 4,800 | $0 | 4/30/2025 | View on chart |
| BR | ▲ Buy | Grant | 50 | $0 | 4/3/2025 | View on chart |
| BR | ▲ Buy | Grant | 15 | $0 | 4/3/2025 | View on chart |
| BR | ▲ Buy | Grant | 147 | $0 | 3/19/2025 | View on chart |
| BR | ▲ Buy | Grant | 52 | $0 | 1/3/2025 | View on chart |
| BR | ▲ Buy | Grant | 15 | $0 | 1/3/2025 | View on chart |
| BR | ▲ Buy | Grant | 152 | $0 | 12/16/2024 | View on chart |
| BR | ▲ Buy | Grant | 458 | $0 | 11/14/2024 | View on chart |
| BR | ▲ Buy | Option Exercise | 6,469 | $292K | 11/11/2024 | View on chart |
| BR | ▼ Sell | Open Market | 3,880 | $881K | 11/11/2024 | View on chart |
| BR | ▲ Buy | Grant | 53 | $0 | 10/3/2024 | View on chart |
| BR | ▲ Buy | Grant | 16 | $0 | 10/3/2024 | View on chart |
| BR | ▲ Buy | Grant | 166 | $0 | 9/23/2024 | View on chart |
| DBD | ▲ Buy | Grant | 3,196 | $0 | 8/6/2024 | View on chart |
| BR | ▲ Buy | Grant | 52 | $0 | 7/5/2024 | View on chart |
| BR | ▲ Buy | Grant | 14 | $0 | 7/5/2024 | View on chart |
| BR | ▲ Buy | Grant | 163 | $0 | 6/13/2024 | View on chart |
| SF | ▲ Buy | Option Exercise | 2,504 | $0 | 6/7/2024 | View on chart |
| BR | ▲ Buy | Grant | 51 | $0 | 4/5/2024 | View on chart |
| BR | ▲ Buy | Grant | 14 | $0 | 4/5/2024 | View on chart |
| BR | ▲ Buy | Grant | 161 | $0 | 3/26/2024 | View on chart |
| BR | ▲ Buy | Grant | 53 | $0 | 1/5/2024 | View on chart |
| BR | ▲ Buy | Grant | 14 | $0 | 1/5/2024 | View on chart |
| BR | ▲ Buy | Grant | 538 | $0 | 11/9/2023 | View on chart |
| BR | ▲ Buy | Grant | 55 | $0 | 10/5/2023 | View on chart |
| BR | ▲ Buy | Grant | 15 | $0 | 10/5/2023 | View on chart |
| BR | ▲ Buy | Grant | 54 | $0 | 7/6/2023 | View on chart |
| BR | ▲ Buy | Grant | 15 | $0 | 7/6/2023 | View on chart |
| SF | ▲ Buy | Option Exercise | 2,641 | $0 | 6/13/2023 | View on chart |
| BR | ▲ Buy | Grant | 63 | $0 | 4/5/2023 | View on chart |
| BR | ▲ Buy | Grant | 18 | $0 | 4/5/2023 | View on chart |
| BR | ▲ Buy | Grant | 63 | $0 | 1/5/2023 | View on chart |
| BR | ▲ Buy | Grant | 16 | $0 | 1/5/2023 | View on chart |
| BR | ▲ Buy | Grant | 227 | $0 | 12/19/2022 | View on chart |
| BR | ▲ Buy | Grant | 627 | $0 | 11/9/2022 | View on chart |
| BR | ▲ Buy | Grant | 51 | $0 | 10/5/2022 | View on chart |
| BR | ▲ Buy | Grant | 13 | $0 | 10/5/2022 | View on chart |
| BR | ▲ Buy | Grant | 192 | $0 | 9/28/2022 | View on chart |
| BR | ▲ Buy | Grant | 12 | $0 | 7/6/2022 | View on chart |
| BR | ▲ Buy | Grant | 49 | $0 | 7/6/2022 | View on chart |
| BR | ▲ Buy | Grant | 250 | $0 | 6/16/2022 | View on chart |
| SF | ▲ Buy | Option Exercise | 1,389 | $0 | 5/31/2022 | View on chart |
| BR | ▲ Buy | Grant | 10 | $0 | 4/5/2022 | View on chart |
| BR | ▲ Buy | Grant | 46 | $0 | 4/5/2022 | View on chart |
| BR | ▲ Buy | Grant | 209 | $0 | 3/24/2022 | View on chart |
| SF | ▲ Buy | Option Exercise | 5,625 | $0 | 1/7/2022 | View on chart |
| BR | ▲ Buy | Grant | 41 | $0 | 1/5/2022 | View on chart |
| BR | ▲ Buy | Grant | 10 | $0 | 1/5/2022 | View on chart |
| BR | ▲ Buy | Grant | 184 | $0 | 12/6/2021 | View on chart |
| BR | ▲ Buy | Grant | 485 | $0 | 11/18/2021 | View on chart |
| BR | ▲ Buy | Grant | 155 | $0 | 10/6/2021 | View on chart |
| BR | ▲ Buy | Grant | 42 | $0 | 10/5/2021 | View on chart |
| BR | ▲ Buy | Grant | 8 | $0 | 10/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Broadridge (BR) Gains 14.3% as Compliance Focus Grows
Broadridge shares have risen 14.3% over the past three months, a move highlighted by recent market analysis. The stock is also drawing attention as a key player in the US compliance sector following a recent penalty involving Bank of America. This growth aligns with the company's status as a dividend growth stock, with an average analyst target price of $213.38.
Broadridge (BR) Gains 14.3% as Compliance Focus Grows. Broadridge shares have risen 14.3% over the past three months, a move highlighted by recent market analysis. The stock is also drawing attention as a key player in the US compliance sector following a recent penalty involving Bank of America. This growth aligns with the company's status as a dividend growth stock, with an average analyst target price of $213.38.